Sonelokimab for Biologic-Naive Psoriatic Arthritis
MoonLake Immunotherapeutics AG
Sonelokimab is being tested in adults with active psoriatic arthritis who have not used biologic drugs, measuring joint symptom improvement after 16 weeks.
Darovasertib and Crizotinib for HLA-A2-Negative Metastatic Uveal
IDEAYA Biosciences
This trial tests first-line darovasertib plus crizotinib in HLA-A2-negative metastatic uveal melanoma, measuring cancer control and survival.
EYP-1901 for Wet Age-Related Macular Degeneration
EyePoint Pharmaceuticals, Inc.
This Phase 3 trial compares EYP-1901 with aflibercept in wet age-related macular degeneration, measuring vision change at one year.
Lutetium-177 Rosopatamab Tetraxetan for Metastatic Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited
This Phase 3 trial tests lutetium-177 rosopatamab tetraxetan in men with PSMA-positive metastatic castration-resistant prostate cancer, measuring time without...
Afrezza Inhaled Insulin for Pediatric Diabetes
Mannkind Corporation
This study tests Afrezza inhaled insulin in children and teens with type 1 or type 2 diabetes, measuring HbA1c blood sugar control at 26 weeks.
Envudeucitinib for Active Systemic Lupus Erythematosus
Alumis Inc
This study tests envudeucitinib in adults with active systemic lupus, measuring overall lupus disease-activity response at 48 weeks.
Tarcocimab and Tabirafusp for Wet Age-Related Macular Degeneration
Kodiak Sciences Inc
This Phase 3 trial tests tarcocimab tedromer and tabirafusp tedromer in wet AMD, measuring vision change at 48 weeks.
ML-004 for Autism Spectrum Disorder
MapLight Therapeutics
This Phase 2 trial tested ML-004 in adolescents and adults with autism, measuring social communication change by Day 110.
Bezisterim for Long COVID Brain Fog and Fatigue
BioVie Inc.
This study tests bezisterim for adults with long COVID brain fog and fatigue, measuring cognitive test performance after 12 weeks.
SION-719 Added to Trikafta for Cystic Fibrosis
Sionna Therapeutics Inc.
SION-719 is being tested with Trikafta in adults with cystic fibrosis, mainly tracking side effects through 57 days.